{"entity":{"id":"julio-delgado","kind":"person","name":"Julio Delgado","aka":[],"tldr":"Barcelona haematologist and senior author of CART19-BE-01, the trial that led Spain to authorise a CAR-T made by a public hospital.","summary":"Julio Delgado is a haematologist in the Department of Hematology at Hospital Clínic de Barcelona and the FRCB-IDIBAPS research institute, according to the affiliation on his 2026 paper on varnimcabtagene autoleucel in mantle cell lymphoma. He is the senior author of the 2021 Molecular Therapy report of CART19-BE-01, the academic trial of the CD19 CAR-T ARI-0001, in which the measurable residual disease-negative complete response rate at day 100 in acute lymphoblastic leukaemia was 71.1%, and an author of the CARTBCMA-HCB-01 report on the hospital's BCMA CAR-T ARI0002h. He also led the ARI-0001 report in chronic lymphocytic leukaemia and Richter's transformation as senior author.","asOf":"2026-11-03","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delgado%20J%5BAuthor%5D%20ARI-0001"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Department of Hematology, Hospital Clínic de Barcelona and FRCB-IDIBAPS; Universitat de Barcelona","institutionId":"hospital-clinic-barcelona","specialisms":["Chronic lymphocytic leukaemia","CAR-T cell therapy","Lymphoid malignancies"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delgado%20J%5BAuthor%5D%20ARI-0001"}],"papers":[{"title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","journal":"Molecular Therapy","year":2021,"doi":"10.1016/j.ymthe.2020.09.027"},{"title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01)","journal":"The Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00222-X"},{"title":"Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma","journal":"HemaSphere","year":2026,"doi":"10.1002/hem3.70388"},{"title":"Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation","journal":"Frontiers in Oncology","year":2022,"doi":"10.3389/fonc.2022.828471"}]},"route":"/people/julio-delgado/","neighbours":{"institution":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"}],"trial":[{"id":"cart19-be-01","kind":"trial","name":"CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cart19-be-01/"},{"id":"cartbcma-hcb-01","kind":"trial","name":"CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cartbcma-hcb-01/"}],"paper":[{"id":"paper-cart19-be-01-mol-ther-2021","kind":"paper","name":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","route":"/key-papers/paper-cart19-be-01-mol-ther-2021/"},{"id":"paper-cartbcma-hcb-01-lancet-oncol-2023","kind":"paper","name":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","route":"/key-papers/paper-cartbcma-hcb-01-lancet-oncol-2023/"}]}}